BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries
Phase 4
Completed
- Conditions
- Gene ExpressionCell ProliferationWound Healing
- Interventions
- Drug: PlaceboDrug: Dexpanthenol (BAY81-2996)
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT00859196
Effect of Riociguat on Bone Metabolism
Phase 1
Completed
- Conditions
- Pharmacology, Clinical
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 17
- Registration Number
- NCT00855660
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Phase 2
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: Sorafenib (Nexavar, BAY43-9006)Drug: Placebo
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 307
- Registration Number
- NCT00855218
- Locations
- 🇪🇸
Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain
🇺🇸Abbott Northwestern Hospital, Minneapolis, Minnesota, United States
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Phase 3
Completed
- Conditions
- Pulmonary Hypertension
- Interventions
- Drug: Riociguat (Adempas, BAY63-2521)Drug: Placebo
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 262
- Registration Number
- NCT00855465
- Locations
- 🇫🇷
Hopital Antoine Beclere, Clamart Cedex, France
🇨🇿Vseobecna fakultni nemocnice, Praha 2, Czechia
AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2672
- Registration Number
- NCT00846911
Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT00847314
Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
Phase 2
Terminated
- Conditions
- Overactive DetrusorMultiple Sclerosis
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT00845338
ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
Phase 2
Completed
- Conditions
- PreventionThromboembolism
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 641
- Registration Number
- NCT00839826
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
Phase 2
Completed
- Conditions
- Venous ThrombosisDeep Vein Thrombosis
- Interventions
- Drug: Xarelto (Rivaroxaban, BAY59-7939)Drug: Enoxaparin/Vitamin K-Antagonist
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 613
- Registration Number
- NCT00839163
Efficacy of Dexpanthenol in Thermic Erythema
Phase 2
Completed
- Conditions
- Erythema
- Interventions
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2013-10-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 55
- Registration Number
- NCT00839462
© Copyright 2025. All Rights Reserved by MedPath